www.ecoanimalhealthgroupplc.com
ECO Animal Health Group plc is a leader in the development, registration and marketing of pharmaceutical products for global animal health markets. Our products for these growth markets promote well-being in animals. Our financial goals are achieved through the careful and responsible application of science to generate value for our shareholders.
ECO Animal Health wins marketing approval in Mexico for dog’s heartworm treatment
ECO Animal Health Group PLC (AIM: EAH) said it has been granted a marketing authorisation in Mexico for Ecoheart Chewable Tablets for dogs.
Ecoheart tablets prevent heartworm disease and are also effective in the treatment and control of roundworms and hookworms in dogs. Canine heartworm infection is transmitted by mosquitoes. It is potentially fatal and requires a monthly preventative treatment.
Ecoheart Chewable Tablets is the first companion animal product for which ECO has received a marketing authorisation in Latin America where the pet sector is an important and growing market. Further marketing authorisations in the key markets of the region are expected.
Chairman Peter Lawrence commented: “We are delighted to add this Ecoheart approval to our Ecomectin range of endectocides, where it is already licensed for sale in Japan. This is a further important registration for the company's portfolio of specialised drugs for animals."
ECO Animal Health Group develops, registers and markets pharmaceutical products promoting wellbeing in animals.
The group announced last month that its two new products, Aivlosin oral powder for pigs and Aivlosin granules for oral solution for medicated drinking water for pheasants, have received positive opinions and were granted registration approval by the European Medicines Agency (EMEA).
The approval from EMEA allows the company to commence active marketing of the products in Europe, an important step in its development of Aivlosin as a global veterinary product and to further extend its marketing reach.
The company is already working on launch and distribution plans for the US market, expecting to receive first marketing authorisations for Aivlosin from the Food and Drug Administration (FDA) in the current year.
The group’s other products include Chlortet, which is aimed at controlling E.coli infections, and performance promoters such as Flaveco, designed to improve efficiency and growth in pigs.
